.

Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
Baxter
Teva
Express Scripts
Chubb
Moodys
Argus Health
Fish and Richardson
McKinsey
Colorcon

Generated: September 24, 2017

DrugPatentWatch Database Preview

Fluticasone propionate; salmeterol xinafoate - Generic Drug Details

« Back to Dashboard

What are the generic sources for fluticasone propionate; salmeterol xinafoate and what is the scope of fluticasone propionate; salmeterol xinafoate freedom to operate?

Fluticasone propionate; salmeterol xinafoate
is the generic ingredient in five branded drugs marketed by Glaxo Grp Ltd and Teva Pharm, and is included in three NDAs. There are thirty-one patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Fluticasone propionate; salmeterol xinafoate has four hundred and forty patent family members in fifty-seven countries.

There are twenty-four drug master file entries for fluticasone propionate; salmeterol xinafoate. Ten suppliers are listed for this compound.

Summary for Generic Name: fluticasone propionate; salmeterol xinafoate

Tradenames:5
Patents:31
Applicants:2
NDAs:3
Drug Master File Entries: see list24
Suppliers / Packagers: see list10
Clinical Trials: see list644
Drug Prices:see low prices
DailyMed Link:fluticasone propionate; salmeterol xinafoate at DailyMed

Pharmacology for Ingredient: fluticasone propionate; salmeterol xinafoate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Pharm
AIRDUO RESPICLICK
fluticasone propionate; salmeterol xinafoate
POWDER;INHALATION208799-002Jan 27, 2017RXYesNo► Subscribe► SubscribeY ► Subscribe
Glaxo Grp Ltd
ADVAIR HFA
fluticasone propionate; salmeterol xinafoate
AEROSOL, METERED;INHALATION021254-003Jun 8, 2006RXYesYes► Subscribe► SubscribeY► Subscribe
Teva Pharm
AIRDUO RESPICLICK
fluticasone propionate; salmeterol xinafoate
POWDER;INHALATION208799-003Jan 27, 2017RXYesYes► Subscribe► SubscribeY ► Subscribe
Glaxo Grp Ltd
ADVAIR HFA
fluticasone propionate; salmeterol xinafoate
AEROSOL, METERED;INHALATION021254-001Jun 8, 2006RXYesYes► Subscribe► SubscribeY► Subscribe
Teva Pharm
AIRDUO RESPICLICK
fluticasone propionate; salmeterol xinafoate
POWDER;INHALATION208799-001Jan 27, 2017RXYesNo► Subscribe► SubscribeY ► Subscribe
Teva Pharm
AIRDUO RESPICLICK
fluticasone propionate; salmeterol xinafoate
POWDER;INHALATION208799-001Jan 27, 2017RXYesNo► Subscribe► SubscribeY ► Subscribe
Glaxo Grp Ltd
ADVAIR HFA
fluticasone propionate; salmeterol xinafoate
AEROSOL, METERED;INHALATION021254-003Jun 8, 2006RXYesYes► Subscribe► SubscribeY► Subscribe
Glaxo Grp Ltd
ADVAIR DISKUS 100/50
fluticasone propionate; salmeterol xinafoate
POWDER;INHALATION021077-001Aug 24, 2000RXYesYes► Subscribe► Subscribe ► Subscribe
Teva Pharm
AIRDUO RESPICLICK
fluticasone propionate; salmeterol xinafoate
POWDER;INHALATION208799-001Jan 27, 2017RXYesNo► Subscribe► SubscribeY ► Subscribe
Glaxo Grp Ltd
ADVAIR HFA
fluticasone propionate; salmeterol xinafoate
AEROSOL, METERED;INHALATION021254-003Jun 8, 2006RXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: fluticasone propionate; salmeterol xinafoate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxo Grp Ltd
ADVAIR HFA
fluticasone propionate; salmeterol xinafoate
AEROSOL, METERED;INHALATION021254-001Jun 8, 2006► Subscribe► Subscribe
Glaxo Grp Ltd
ADVAIR DISKUS 500/50
fluticasone propionate; salmeterol xinafoate
POWDER;INHALATION021077-003Aug 24, 2000► Subscribe► Subscribe
Glaxo Grp Ltd
ADVAIR DISKUS 100/50
fluticasone propionate; salmeterol xinafoate
POWDER;INHALATION021077-001Aug 24, 2000► Subscribe► Subscribe
Glaxo Grp Ltd
ADVAIR HFA
fluticasone propionate; salmeterol xinafoate
AEROSOL, METERED;INHALATION021254-002Jun 8, 2006► Subscribe► Subscribe
Glaxo Grp Ltd
ADVAIR DISKUS 500/50
fluticasone propionate; salmeterol xinafoate
POWDER;INHALATION021077-003Aug 24, 2000► Subscribe► Subscribe
Glaxo Grp Ltd
ADVAIR DISKUS 250/50
fluticasone propionate; salmeterol xinafoate
POWDER;INHALATION021077-002Aug 24, 2000► Subscribe► Subscribe
Glaxo Grp Ltd
ADVAIR DISKUS 250/50
fluticasone propionate; salmeterol xinafoate
POWDER;INHALATION021077-002Aug 24, 2000► Subscribe► Subscribe
Glaxo Grp Ltd
ADVAIR HFA
fluticasone propionate; salmeterol xinafoate
AEROSOL, METERED;INHALATION021254-001Jun 8, 2006► Subscribe► Subscribe
Glaxo Grp Ltd
ADVAIR DISKUS 250/50
fluticasone propionate; salmeterol xinafoate
POWDER;INHALATION021077-002Aug 24, 2000► Subscribe► Subscribe
Glaxo Grp Ltd
ADVAIR DISKUS 250/50
fluticasone propionate; salmeterol xinafoate
POWDER;INHALATION021077-002Aug 24, 2000► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: fluticasone propionate; salmeterol xinafoate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,737,674Dose counters for inhalers, inhalers and methods of assembly thereof► Subscribe
9,533,111Dose counters for inhalers, inhalers and methods of assembly thereof► Subscribe
6,655,381 Pre-metered dose magazine for breath-actuated dry powder inhaler► Subscribe
2,006,107,948► Subscribe
6,032,666 Inhalation device► Subscribe
9,526,851Dose counters for inhalers, inhalers and methods of assembly thereof► Subscribe
5,860,419 Inhalation device► Subscribe
9,108,010Dose counters for inhalers, inhalers and methods of assembly thereof► Subscribe
9,345,664Process for preparing a medicament► Subscribe
5,590,645 Inhalation device► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: fluticasone propionate; salmeterol xinafoate

Country Document Number Estimated Expiration
Spain2222525► Subscribe
Spain2544277► Subscribe
Eurasian Patent Organization201300232► Subscribe
Eurasian Patent Organization201690641► Subscribe
Spain2382734► Subscribe
Japan2007289716► Subscribe
Canada2552468► Subscribe
Eurasian Patent Organization201690463► Subscribe
South Korea20130103828► Subscribe
Australia2001270112► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB08/026United Kingdom► SubscribePRODUCT NAME: FLUTICASONE FUROATE AND SOLVATES THEREOF; REGISTERED: UK EU/1/07/434/001 20080111; UK EU/1/07/434/002 20080111; UK EU/1/07/434/003 20080111
C0067France► SubscribePRODUCT NAME: AZELASTINE OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE; NAT. REGISTRATION NO/DATE: NL41755 20130925; FIRST REGISTRATION: SK - 24/0055/13-S 20130215
269Luxembourg► SubscribePRODUCT NAME: AZELASTINE,OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUICI,ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE
C0014France► SubscribePRODUCT NAME: FLUTICASONE FUROATE; REGISTRATION NO/DATE: EU/1/07/434/001 20080111
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
McKinsey
Chinese Patent Office
Colorcon
Healthtrust
Moodys
Mallinckrodt
Covington
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot